Disclosed herein, inter alia, are compositions and methods for inhibiting DNA2.

Described are methods of treating solid cancers in a subject. The methods comprise the steps of administering to the subject having the solid cancer or prone of getting the solid cancer an antagonist of PTPN22, or the functional part of PTPN22, and treating the solid cancer. Methods comprising use of other anticancer agents and adjuvants in conjunction with PTPN22 inhibitors are also provided.

Described are methods of treating solid cancers in a subject. The methods comprise the steps of administering to the subject having the solid cancer or prone of getting the solid cancer an antagonist of PTPN22, or the functional part of PTPN22, and treating the solid cancer. Methods comprising use of other anticancer agents and adjuvants in conjunction with PTPN22 inhibitors are also provided.

The present disclosure is directed to disclosed compounds that modulate e.g., address underlying defects in cellular processing of CFTR activity.

The present disclosure is directed to disclosed compounds that modulate e.g., address underlying defects in cellular processing of CFTR activity.

Provided herein is a polymorphic form of Ivacaftor, namely APO-I, as well as processes for the preparation and pharmaceutical compositions of the same. Also, provided is a new solvate of Ivacaftor, processes for its preparation and use in the preparation of pure Ivacaftor.

Provided herein is a polymorphic form of Ivacaftor, namely APO-I, as well as processes for the preparation and pharmaceutical compositions of the same. Also, provided is a new solvate of Ivacaftor, processes for its preparation and use in the preparation of pure Ivacaftor.

This invention relates to compounds of Formula I:

##STR00001##

and pharmaceutically acceptable salts thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering a CFTR potentiator.

This invention relates to compounds of Formula I:

##STR00001##

and pharmaceutically acceptable salts thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering a CFTR potentiator.

A gel composition for use in subterranean formations is disclosed. The composition can comprise a base fluid, a cross-linkable polymer that is soluble in the base fluid, a nonionic surfactant and a cross-linking agent. The gel composition has improved crosslinked stability. The gel composition can be injected into the subterranean formation as a fracturing fluid and allowed to penetrate the formation. Preferably, the gel composition effectively blocks the water-bearing regions while the oil or gas producing regions are left unblocked so that the oil or gas can be recovered.